Citigroup’s Cymabay Therapeutics CBAY Stock Holding History

Citigroup’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,000	Closed	-$709K	–	5907
2023 Q4	$709K	Buy	+30,000	New	+$534K	﹤0.01%	3132
2023 Q2	–	Sell	-155,000	Closed	-$1.35M	–	5792
2023 Q1	$1.35M	Buy	155,000 +75,000	+94%	+$600K	﹤0.01%	2323
2022 Q4	$502K	Buy	80,000 +35,000	+78%	+$133K	﹤0.01%	3165
2022 Q3	$158K	Buy	+45,000	New	+$162K	﹤0.01%	3872
2019 Q3	–	Sell	-105,500	Closed	-$755K	–	7850
2019 Q2	$755K	Buy	+105,500	New	+$1.19M	﹤0.01%	3990

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's CBAY Position: Q1 2024 in Review

Citigroup sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 47,005 shares — an estimated $1.11M sold.

Citigroup first reported a position in CBAY in Q3 2014 and held it in 27 quarters. The position peaked at $5.08M in Q3 2019. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Citigroup reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Citigroup sold 47,005 Cymabay Therapeutics shares in Q1 2024, an estimated $1.11M.
Citigroup first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 27 quarters.
Citigroup's Cymabay Therapeutics position peaked at $5.08M in Q3 2019.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.